Raphael Pharmaceutical (RAPH) Assets (2020 - 2026)

Raphael Pharmaceutical has disclosed Assets across 7 years of filings, most recently posting $7000.0 for Q2 2026.

• In Q2 2026, Assets fell 76.67% year-over-year to $7000.0; the TTM figure through Jun 2026 stood at $7000.0 (down 76.67% YoY), while the FY2025 annual figure was $53000.0, up 96.3% from the prior year.
• Assets came in at $7000.0 for Q2 2026 at Raphael Pharmaceutical, down from $53000.0 in the prior quarter.
• In the past five years, Assets ranged from a high of $403000.0 in Q3 2023 to a low of $7000.0 in Q3 2025.
• Average Assets over 5 years is $146470.6, with a median of $121000.0 recorded in 2022.
• Year-over-year, Assets soared 233.06% in 2023 and tumbled 88.7% in 2024.
• Over 5 years, Assets stood at $333000.0 in 2022, then declined by 28.23% to $239000.0 in 2023, then plunged by 88.7% to $27000.0 in 2024, then surged by 96.3% to $53000.0 in 2025, then tumbled by 86.79% to $7000.0 in 2026.
• Per Business Quant data, the three most recent Assets figures were $7000.0 in Q2 2026, $53000.0 in Q4 2025, and $7000.0 in Q3 2025.